Dr O’Connor entered the pharmaceutical industry in 1989 designing and executing Phase II/III studies in Europe. He joined Pfizer in 1994, originally with the Global Research & Development group in the UK, working in neuroscience development with responsibility for antipsychotic and neuroprotective agents. In 1996 he moved to Pfizer HQ in New York as Medical Director Neuroscience, leading the strategic development and launch of a novel antipsychotic, including direction of the associated global phase IIIb/IV clinical program.
In 2000 he assumed responsibility for Medical Affairs for Pfizer’s European operations, based in New York, and has since held medical affairs posts of increasing responsibility including oversight of clinical operations and regulatory affairs.
Since January 2014 he has been Senior Vice-President and Head of Global Medical Affairs for Pfizer Innovative Pharma Business, with responsibility for more than a thousand colleagues operating in over 100 countries. His interests include development and augmentation of medical colleagues’ skills and capabilities and the use of information technology to enhance effective and compliant relationships with healthcare providers.
Dr O’Connor qualified in Medicine from the University of Liverpool in 1978 and practiced initially in internal and family medicine. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).
IFAPP Academy provides an online, continuing professional development course, Medical Affairs in Medicines Development, resulting in the Professional Certification, Certified Medicines Development (CMD).